Zhenfeng Zhang

Learn More
“Certificateless public-key cryptosystem” is a new and attractive paradigm, which avoids the inherent key escrow property in identity-based public-key cryptosystems, and does not need expensive certificates as in the public key infrastructure. A strong security model for certificateless public key encryption was established by Al-Riyami and Paterson in(More)
Human non-small cell lung cancers (NSCLCs) with activating mutations in EGFR frequently respond to treatment with EGFR-targeted tyrosine kinase inhibitors (TKIs), such as erlotinib, but responses are not durable, as tumors acquire resistance. Secondary mutations in EGFR (such as T790M) or upregulation of the MET kinase are found in over 50% of resistant(More)
Identity-based (ID-based) public key cryptosystem can be a good alternative for certificate-based public key setting, especially when efficient key management and moderate security are required. A proxy signature scheme permits an entity to delegate its signing rights to another entity. But to date, no ID-based proxy signature scheme with provable security(More)
Certificateless cryptography involves a Key Generation Center (KGC) which issues a partial key to a user and the user also independently generates an additional public/secret key pair in such a way that the KGC who knows only the partial key but not the additional secret key is not able to do any cryptographic operation on behalf of the user; and a third(More)
Mitogen-activated protein kinase (MAPK) pathway signaling plays an important role in the majority of non-small-cell lung cancers (NSCLCs). In a prior microarray analysis of epidermal growth factor receptor (EGFR) inhibition in NSCLC cell lines, we noted that several dual specificity phosphatases (DUSPs) were among the most highly and immediately regulated(More)
The development of EGFR tyrosine kinase inhibitors for clinical use in non-small cell lung cancer and the subsequent discovery of activating EGFR mutations have led to an explosion of knowledge in the fields of EGFR biology, targeted therapeutics and lung cancer research. EGFR-mutated adenocarcinoma of the lung has clearly emerged as a unique clinical(More)
Archaea contain a variety of chromatin proteins consistent with the evolution of different genome packaging mechanisms. Among the two main kingdoms in the Archaea, Euryarchaeota synthesize histone homologs, whereas Crenarchaeota have not been shown to possess a chromatin protein conserved at the kingdom level. We report the identification of Cren7, a novel(More)